Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28002200 | 0.92 | ADORA2A (0.35) | ADORA2AADORA2BALDH1A1NTRK1IRAK4 | |
| Urea SCHEMBL28122176 | 0.88 | AXL (0.34) | ADORA2AADORA2BALDH1A1NTRK1KDM4E | |
| SCHEMBL27747567 | 0.87 | AXL (0.41) | ALDH1A1KDM4ETDP1AXLMKNK1 | |
| SCHEMBL32388 | 0.87 | — | — | |
| Formaldehyde SCHEMBL28037402 | 0.85 | AXL (0.37) | ALDH1A1NTRK1KDM4ETDP1AXL | |
| Hydrochloric Acid SCHEMBL21803551 | 0.85 | AXL (0.39) | ALDH1A1KDM4ETDP1AXLMKNK1 | |
| Hydrazine SCHEMBL5897595 | 0.83 | AXL (0.38) | ALDH1A1NTRK1KDM4ETDP1AXL | |
| SCHEMBL2107756 | 0.82 | ALDH1A1 (0.33) | ADORA2AADORA2BALDH1A1NTRK1AXL | |
| Pyridine SCHEMBL27578790 | 0.81 | EGFR (0.37) | ALDH1A1KDM4ETDP1AXLMKNK1 | |
| Pyrimidine SCHEMBL27714628 | 0.79 | EGFR (0.38) | ALDH1A1KDM4ETDP1AXLMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8987278-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-24 | — | — | US | disclosed |
| US-20130289054-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-10-31 | — | — | US | disclosed |
| EP-2634191-A1 | Process for preparing derivatives of thienopyrimidinedione | Glenmark Pharmaceuticals S.A. (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-8507503-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-13 | — | — | US | disclosed |
| EP-2411396-B1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120295924-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-22 | — | — | US | disclosed |
| EP-2411396-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109334-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-4898867-A | ANTIDIABETIC AGENT | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1990-02-06 | — | — | US | disclosed |
| EP-0335979-A1 | THIENOPYRIMIDINE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | ADORA2A 44/4885ADORA2B 102/4885ALDH1A1 475/4885 |
| US-20130289054-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | ADORA2A 44/4885ADORA2B 102/4885ALDH1A1 475/4885 |
| US-20120295924-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | ADORA2A 44/4885ADORA2B 102/4885ALDH1A1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.